跳至主要内容
临床试验/NCT05652725
NCT05652725已完成不适用

Radicle™ Clarity: A Randomized, Blinded, Placebo-Controlled Direct-to-Consumer Study of Health and Wellness Products on Cognitive Function and Other Health Outcomes

Radicle Science2 个研究点 分布在 1 个国家目标入组 4,826 人开始时间: 2023年1月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4,826
试验地点
2
主要终点
Change in cognition (mental clarity)

研究概览

简要总结

A randomized, blinded, placebo-controlled direct-to-consumer study of health and wellness products on mental clarity and other health outcomes

详细描述

This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for better concentration, (2) indicate an interest in taking a health and wellness product to potentially help their concentration, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded. Those taking certain medications will be excluded.

Self-reported data are collected electronically from eligible participants over 7 weeks. Participant reports of health indicators will be collected during baseline, throughout the active period of study product use, and in a final survey. All study assessments will be electronic; there are no in-person visits or assessments for this real-world evidence study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

盲法说明

The investigator is blinded to the participants assigned study products. Participants are blinded to the study product they received.

入排标准

年龄范围
21 Years 至 105 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
  • Resides in the United States
  • Endorses better concentration as a primary desire
  • Selects concentration and/or looking to improve their concentration as a reason for their interest in taking a health and wellness product
  • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study

排除标准

  • Reports being pregnant, trying to become pregnant, or breastfeeding
  • Unable to provide a valid US shipping address and mobile phone number
  • The calculated validated health survey (PRO) score during enrollment represents less than mild impairment or severity
  • Reports a diagnosis of liver or kidney disease
  • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
  • Unable to read and understand English
  • Reports current enrollment in a clinical trial
  • Lack of reliable daily access to the internet
  • Reports current or recent (within 3 months) use of chemotherapy or immunotherapy
  • Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied or a substantial safety risk: Anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, or MAOIs (monoamine oxidase inhibitors)
  • Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias

结局指标

主要结局

Change in cognition (mental clarity)

时间窗: 6 weeks

Mean difference in cognition score as assessed by Patient Reported Outcome Measurement System (PROMIS) Cognitive Function Short Form 8A (scale 8-40; where the higher scores correspond to greater cognitive function)

次要结局

  • Change in executive functioning(6 weeks)
  • Change in sleep quality(6 weeks)
  • Change in mood (emotional distress)(6 weeks)
  • Minimal clinical importance difference (MCID) in cognitive function(6 weeks)
  • Change in energy (fatigue)(6 weeks)
  • Change in libido(6 weeks)
  • Change in anxiety(6 weeks)

研究者

发起方
Radicle Science
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验